Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Elastomeric matrix release kinetics: BayerRecent Research Landscape

Chemical instability and bitter taste profiles in continuous tablet manufacturing lead to poor patient compliance and batch rejection. This system engineers the chemical environment to mask bitterness while maintaining structural integrity during rapid processing.

What technical problems is Bayer addressing in Elastomeric matrix release kinetics?

Uncontrolled drug release kinetics

(22)evidences

Low bioavailability and crystallization of hydrophobic compounds in topical or oral formulations. Improving solubility ensures consistent therapeutic delivery and prevents physical instability.

Active ingredient sedimentation instability

(16)evidences

Premature degradation of pyrethroids and insecticidal mixtures in liquid concentrates. Preventing chemical breakdown ensures long-term potency and shelf-life reliability.